NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
NewsRx | Free Newsletters
 
----------
------------
NewsRx on Facebook
-----
NewsRx Passes
Press Release Submissions
PR Login
-----
2008 Award Logo
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
-----
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Security by Verisign

Phytochemicals


Return to Library

Free Phytochemicals Articles


Studies by S. Panda and co-authors describe new findings in therapy



2009 JUN 29 - (NewsRx.com) -- "Doxorubicin is a common chemotherapeutic anticancer drug. Its use is associated with adverse effects including cardiotoxicity," scientists writing in the journal Cardiovascular Therapeutics report.

"Several therapeutics interventions have been attempted to reduce the toxicity and to improve the efficacy of the drug. However, on phytochemicals very few investigations have been made. In the present study we have evaluated the potential of a cardenolide, periplogenin, isolated from the leaves of Aegle marmelos in protecting the doxorubicin induced cardiotoxicity and lipid peroxidation (LPO) in rats. Doxorubicin induced cardiac and hepatotoxicity were characterized by marked biochemical changes including an increase in serum creatine kinase-MB (CK-MB), glutamate-pyruvate transaminase (SGPT), and tissue LPO, with a decrease in superoxide dismutase (SOD), catalase (CAT), and glutathione (GSH). It also increased the levels of different serum lipids, but decreased the amount of high-density lipoprotein (HDL). Cotherapy of the test cardenolide and doxorubicin for 4 weeks reversed all these adverse effects. However, out of three different concentrations (12.5, 25, and 50 mg/kg p.o.) of the test periplogenin, 25 mg/kg appeared to be most effective. When its efficacy was compared with that of vitamin E (alpha-tocopherol) the isolated compound exhibited a better therapeutic potential. The isolated periplogenin from the leaves of A. marmelos could potentially inhibit doxorubicin-induced cardiovascular problems in rats," wrote S. Panda and colleagues.

The researchers concluded: "However, its moderate dose was found to be most effective."

Panda and colleagues published their study in Cardiovascular Therapeutics (Periplogenin-3-O- -D-Glucopyranosyl -(1->6)- -D-Glucopyaranosyl- -(1->4) -D-Cymaropyranoside, Isolated from Aegle marmelos Protects Doxorubicin Induced Cardiovascular Problems and Hepatotoxicity in Rats. Cardiovascular Therapeutics, 2009;27(2):108-116).

Additional information can be obtained by contacting S. Panda, DeviAhiliya University, School Life Science, Khandwa Rd. Complex, Indore 452001, Madhya Pradesh, India.

The publisher of the journal Cardiovascular Therapeutics can be contacted at: Wiley-Blackwell Publishing, Inc., Commerce Place, 350 Main St., Malden 02148, MA, USA.

Keywords: India, Indore, Alternative Medicine, Anticancer Therapy, Biochemical, Biotechnology, Cardiology, Cardiovascular, Creatine, Dietary Supplement, Doxorubicin Hydrochloride, Drugs, Enzyme Research, Gastroenterology, Kinase, Micronutrient, Pharmaceuticals, Phytochemicals, Therapy, Transaminase, Treatment.

This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.

NewsRx NewsRx NewsRx
-----------------------
PR Login